Revolution Medicines Prices $2 Billion Upsized Public Offerings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 15 2026
0mins
Source: NASDAQ.COM
- Upsized Financing: Revolution Medicines announced a total public offering of $2 billion, including 10.56 million shares priced at $142 each, expected to generate approximately $1.5 billion in gross proceeds, significantly enhancing its capital base to support future R&D and commercialization efforts.
- Convertible Notes Issuance: The company is also issuing $500 million in 0.50% convertible senior notes due 2033, with an initial conversion price of approximately $198.80 per share, representing a 40% premium to the common stock offering price, providing investors with potential capital appreciation while offering long-term financing support to the company.
- Underwriter Option: Revolution granted underwriters a 30-day option to purchase an additional 1.58 million shares, further enhancing financing flexibility and responsiveness to market demand, reflecting a positive response to investor interest.
- Positive Market Reaction: Following the financing announcement, Revolution's stock rose 7.86% to $147.01 on Nasdaq, although it slightly declined by 0.66% in overnight trading, indicating overall investor confidence in the company's future prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RVMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RVMD
Wall Street analysts forecast RVMD stock price to fall
20 Analyst Rating
20 Buy
0 Hold
0 Sell
Strong Buy
Current: 153.730
Low
67.00
Averages
86.00
High
147.00
Current: 153.730
Low
67.00
Averages
86.00
High
147.00
About RVMD
Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. The company’s RAS(ON) inhibitors are daraxonrasib (RMC-6236), an RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), an RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are in clinical development. The Company’s pipeline also focuses on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biotech Fund Sells Erasca Stake After 700% Rally
- Share Reduction Details: Paradigm Biocapital Advisors disclosed the sale of 3,766,393 shares of Erasca in Q1 2026, valued at approximately $44.52 million, indicating a cautious approach to market volatility.
- Holding Proportion Change: Following this sale, Paradigm's stake in Erasca now represents 3.44% of its 13F AUM, reflecting a relative decline in importance within its portfolio and suggesting a reallocation towards other investments.
- Stock Performance: As of May 14, 2026, Erasca shares were priced at $10.37, marking a remarkable 716.5% increase over the past year, significantly outperforming the S&P 500 by 689.24 percentage points, demonstrating strong market confidence in its potential products.
- Investment Risk Advisory: Despite promising early clinical trial results, a recent incident involving a patient death led to a 46% drop in stock price in a single day, highlighting the high-risk nature of biotech investments and the need for investors to carefully assess timing.
See More
Boxer Capital Acquires $17.55 Million Stake in Corvus Pharmaceuticals
- New Investment Disclosure: Boxer Capital Management disclosed a new position in Corvus Pharmaceuticals by acquiring 1,100,000 shares in Q1 2026 for an estimated $17.55 million, indicating strong confidence in the company, particularly as its stock has surged 250% over the past year.
- Quarter-End Position Value: As of March 31, 2026, Boxer Capital's position in Corvus was valued at $16.09 million, reflecting an active investment strategy amidst stock price fluctuations, further solidifying its standing in the biotech sector.
- Financial Overview: Corvus Pharmaceuticals ended Q1 2026 with $236.7 million in cash and marketable securities, with management stating that this funding will support operations into Q2 2028, despite posting a quarterly net loss of $13.7 million as R&D spending continues to rise.
- Clinical Trial Progress: Corvus is conducting a Phase 2 trial expected to enroll approximately 200 patients, with preliminary data showing that 75% of patients maintained effective responses after treatment cessation, indicating potential in immune modulation that may attract further investor interest.
See More
Revolution Medicines Q1 2026 Earnings Call Insights
- Survival Rate Improvement: In the RASolute 302 trial, daraxonrasib monotherapy demonstrated a significant improvement in overall survival compared to chemotherapy, achieving a median survival exceeding one year and a 60% reduction in the risk of death in the intent-to-treat population, marking a major breakthrough in treating metastatic pancreatic cancer.
- FDA Application Plans: The company intends to submit a new drug application under the FDA Commissioner's National Priority Voucher Program, with CEO Goldsmith emphasizing this as a strategic priority, while the FDA has also approved the initiation of an expanded access treatment protocol, enhancing patient treatment opportunities.
- Improved Financial Position: As of Q1 2026, the company reported $1.9 billion in cash and investments, bolstered by $2.1 billion in net proceeds from April offerings, significantly strengthening its financial position and providing funding for ongoing R&D and market initiatives.
- Rising Operating Expenses: Due to accelerated R&D efforts, Q1 R&D expenses reached $344 million, up from $205.7 million year-over-year, while G&A expenses increased from $35 million to $101.3 million, resulting in a net loss of $453.8 million, reflecting the company's commitment to advancing clinical trials and market readiness.
See More
Revolution (RVMD) Q1 2026 Earnings Transcript
See More
Revolution Medicines Reports Clinical Trial Results for Daraxonrasib
- Clinical Trial Progress: Revolution Medicines published data from the Phase 1/2 trial of daraxonrasib in the NEJM, demonstrating promising antitumor activity in previously treated metastatic RAS mutant pancreatic ductal adenocarcinoma patients, supporting the initiation of its global Phase 3 trial.
- Survival Rate Improvement: The RASolute 302 trial showed daraxonrasib provided unprecedented overall survival benefits compared to standard chemotherapy, indicating its potential to offer new treatment options for pancreatic cancer patients.
- FDA Breakthrough Therapy Designation: Daraxonrasib received Breakthrough Therapy and Orphan Drug Designation from the FDA, highlighting its significant potential in treating metastatic pancreatic ductal adenocarcinoma, which boosts investor and market confidence.
- Strong Market Demand: Pancreatic cancer is one of the deadliest cancers in the U.S., with approximately 60,000 diagnosed and 50,000 deaths annually, making daraxonrasib's development crucial to meet this high demand and improve patient survival and quality of life.
See More
Analysis of XBI ETF Trading Dynamics
- Price Fluctuation Analysis: XBI's 52-week low is $75.68 per share and high is $139.19, with the latest trade at $135.87, indicating stability near the high, which may attract investor interest in its technical performance.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average provides valuable insights for investors, aiding in market trend assessment and potential buying opportunities.
- ETF Unit Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify significant inflows (new units created) or outflows (old units destroyed), which can influence price movements of the underlying components within the ETF.
See More
Biotech Fund Sells Erasca Stake After 700% Rally
- Share Reduction Details: Paradigm Biocapital Advisors disclosed the sale of 3,766,393 shares of Erasca in Q1 2026, valued at approximately $44.52 million, indicating a cautious approach to market volatility.
- Holding Proportion Change: Following this sale, Paradigm's stake in Erasca now represents 3.44% of its 13F AUM, reflecting a relative decline in importance within its portfolio and suggesting a reallocation towards other investments.
- Stock Performance: As of May 14, 2026, Erasca shares were priced at $10.37, marking a remarkable 716.5% increase over the past year, significantly outperforming the S&P 500 by 689.24 percentage points, demonstrating strong market confidence in its potential products.
- Investment Risk Advisory: Despite promising early clinical trial results, a recent incident involving a patient death led to a 46% drop in stock price in a single day, highlighting the high-risk nature of biotech investments and the need for investors to carefully assess timing.
See More
Boxer Capital Acquires $17.55 Million Stake in Corvus Pharmaceuticals
- New Investment Disclosure: Boxer Capital Management disclosed a new position in Corvus Pharmaceuticals by acquiring 1,100,000 shares in Q1 2026 for an estimated $17.55 million, indicating strong confidence in the company, particularly as its stock has surged 250% over the past year.
- Quarter-End Position Value: As of March 31, 2026, Boxer Capital's position in Corvus was valued at $16.09 million, reflecting an active investment strategy amidst stock price fluctuations, further solidifying its standing in the biotech sector.
- Financial Overview: Corvus Pharmaceuticals ended Q1 2026 with $236.7 million in cash and marketable securities, with management stating that this funding will support operations into Q2 2028, despite posting a quarterly net loss of $13.7 million as R&D spending continues to rise.
- Clinical Trial Progress: Corvus is conducting a Phase 2 trial expected to enroll approximately 200 patients, with preliminary data showing that 75% of patients maintained effective responses after treatment cessation, indicating potential in immune modulation that may attract further investor interest.
See More
Revolution Medicines Q1 2026 Earnings Call Insights
- Survival Rate Improvement: In the RASolute 302 trial, daraxonrasib monotherapy demonstrated a significant improvement in overall survival compared to chemotherapy, achieving a median survival exceeding one year and a 60% reduction in the risk of death in the intent-to-treat population, marking a major breakthrough in treating metastatic pancreatic cancer.
- FDA Application Plans: The company intends to submit a new drug application under the FDA Commissioner's National Priority Voucher Program, with CEO Goldsmith emphasizing this as a strategic priority, while the FDA has also approved the initiation of an expanded access treatment protocol, enhancing patient treatment opportunities.
- Improved Financial Position: As of Q1 2026, the company reported $1.9 billion in cash and investments, bolstered by $2.1 billion in net proceeds from April offerings, significantly strengthening its financial position and providing funding for ongoing R&D and market initiatives.
- Rising Operating Expenses: Due to accelerated R&D efforts, Q1 R&D expenses reached $344 million, up from $205.7 million year-over-year, while G&A expenses increased from $35 million to $101.3 million, resulting in a net loss of $453.8 million, reflecting the company's commitment to advancing clinical trials and market readiness.
See More
Revolution (RVMD) Q1 2026 Earnings Transcript
See More
Revolution Medicines Reports Clinical Trial Results for Daraxonrasib
- Clinical Trial Progress: Revolution Medicines published data from the Phase 1/2 trial of daraxonrasib in the NEJM, demonstrating promising antitumor activity in previously treated metastatic RAS mutant pancreatic ductal adenocarcinoma patients, supporting the initiation of its global Phase 3 trial.
- Survival Rate Improvement: The RASolute 302 trial showed daraxonrasib provided unprecedented overall survival benefits compared to standard chemotherapy, indicating its potential to offer new treatment options for pancreatic cancer patients.
- FDA Breakthrough Therapy Designation: Daraxonrasib received Breakthrough Therapy and Orphan Drug Designation from the FDA, highlighting its significant potential in treating metastatic pancreatic ductal adenocarcinoma, which boosts investor and market confidence.
- Strong Market Demand: Pancreatic cancer is one of the deadliest cancers in the U.S., with approximately 60,000 diagnosed and 50,000 deaths annually, making daraxonrasib's development crucial to meet this high demand and improve patient survival and quality of life.
See More
Analysis of XBI ETF Trading Dynamics
- Price Fluctuation Analysis: XBI's 52-week low is $75.68 per share and high is $139.19, with the latest trade at $135.87, indicating stability near the high, which may attract investor interest in its technical performance.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average provides valuable insights for investors, aiding in market trend assessment and potential buying opportunities.
- ETF Unit Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify significant inflows (new units created) or outflows (old units destroyed), which can influence price movements of the underlying components within the ETF.
See More
